To achieve self-reliance and minimise import dependency in the country's essential bulk drugs, the Department of Pharmaceuticals initiated the Segments' with a cumulative outlay of Rs. 6,940 crore (US$ 951.27 million) from FY21 to FY30. Under Target Segment I', five applications with an investment of Rs. 3,761 crore (US$ 515.52 million) have been approved. The Production Linked Incentive (PLl) scheme for the pharmaceutical sector in India is allocated Rs. 2,444.9 crore (US$ 279.77 million) for the